GRAIL, LLC is a leading biotechnology firm specializing in advanced cancer diagnostics, particularly through its innovative blood tests designed for multi-cancer early detection (MCED). Utilizing proprietary genomic technologies, the company is committed to enhancing precision medicine by offering vital insights for proactive health management and improving patient outcomes. GRAIL is poised to address critical gaps in cancer screening and diagnostics, establishing itself as a pivotal entity in the dynamic oncology landscape, with the potential to significantly impact the future of cancer care.
| Revenue (TTM) | $166.60M |
| Gross Profit (TTM) | $77.77M |
| EBITDA | $-398.22M |
| Operating Margin | -385.30% |
| Return on Equity | -17.30% |
| Return on Assets | -13.00% |
| Revenue/Share (TTM) | $3.80 |
| Book Value | $54.82 |
| Price-to-Book | 2.17 |
| Price-to-Sales (TTM) | 32.62 |
| EV/Revenue | 27.78 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 3.70% |
| Shares Outstanding | $44.75M |
| Float | $34.41M |
| % Insiders | 4.78% |
| % Institutions | 86.69% |
Volatility is currently expanding
GRAL is cutting Galleri prices to boost adoption ahead of an expected early 2027 FDA decision, even as pricing pressure weighs on revenue growth and margins.
In Q3 2026, the portfolio underperformed its benchmark, the MSCI All Country World Index. On a positive note, our stock selection in the health care sector led to significant outperformance relative to those in the benchmark. Numerous portfolio moves were made during the quarter, but our focus remained on our three main investment themes: electrification, financials and aerospace and defense.
FDA Advisory Committee Voted in Favor of Approval of GRAIL's Galleri Multi-Cancer Early Detection Test Q3 Galleri ® Test Volume Increased ~24% to More Than 56,000 Year-Over-Year, Year-to-Date Test Volume Increased ~36% to More Than 174,000 Q3 Galleri Revenue Grew 14% Year-Over-Year to $37.3 Million SUNNYVALE, Calif., Nov. 4, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the third quarter of 2026.
GRAL's Q3 earnings should have benefited from rising Galleri test adoption, expanding digital health partnerships and growing clinical evidence of cancer detection.
SUNNYVALE, Calif., Oct. 27, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the UBS Global Healthcare Conference in Palm Beach, FL on Tuesday, Nov. 10 at 11:00 a.m.
The S&P 500 recently sat just 2.5% below its all-time high. Look past the index, though, and the picture gets uglier.
SUNNYVALE, Calif., Oct. 21, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the third quarter 2026 following the close of market on Wednesday, Nov. 4, 2026.
For a rare breed of travel enthusiast, the free toiletry pouches are more than a throwaway convenience. They're a trip down memory lane.
Jim Cramer sees three stocks with very different amounts of bad news or good news already baked into their prices, and figuring out which side each sits on changes everything about whether to buy.
GRAIL to Present Six Abstracts at the Early Detection of Cancer Conference (EDCC) Spanning Clinical Performance, Health Equity, and Real-World Implementation of Multi-Cancer Early Detection GRAIL to Present Two Abstracts at the European Society for Medical Oncology (ESMO) Congress, Across the Cancer Diagnostic Journey and Real-World Evidence SUNNYVALE, Calif., Oct. 5, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present additional data from both the NHS-Galleri trial and the PATHFINDER 2 study further evaluating the Galleri® multi-cancer early detection (MCED) test at the Early Detection of Cancer Conference (EDCC) in Edinburgh, the United Kingdom, taking place Oct. 6-8, 2026, and at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain taking place Oct. 23-27, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on GRAL and any ticker you trade — then tracks every position and per-strategy win rate.
